Ebola Vaccine Market Explore Future Growth 2018-2026 by Global Top Players – Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, Novavax

Coherent Market Insights has announced the addition of the “Ebola Vaccine Market Size Status and Forecast 2026”, The report classifies the global Ebola Vaccine Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Ebola Vaccine Speaker market, analyzes and researches the Ebola Vaccine Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, Novavax

Request a sample copy of Ebola vaccine market: https://www.coherentmarketinsights.com/insight/request-sample/1365

Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.

Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.

On the basis of virus strain, the global Ebola vaccine market is segmented into:

-Recombinant vesicular stomatitis virus-Zaire Ebola virus
-Chimpanzee Adeno virus type 3-Zaire Ebola virus
-Adeno virus serotype 26- Zaire Ebola Virus

According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology.

In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.

Else place an Inquire before Purchase “Ebola Vaccine Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1365

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.